Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy.

The American Journal of Pathology
Jeong-Hun KimKyu-Won Kim

Abstract

Vision loss in diabetic retinopathy is due to macular edema characterized by increased vascular permeability, which involves phosphorylation associated with activation of protein kinase C (PKC) isoforms. Herein, we demonstrated PKC delta inhibition could prevent blood-retinal barrier breakdown in diabetic retinopathy. Increased vascular permeability of diabetic retina was accompanied by a decrease of zonula occludens (ZO)-1 and ZO-2 expression. In diabetic retina and advanced glycation end product-treated human retinal microvascular endothelial cells, vascular leakage and loss of ZO-1 and ZO-2 on retinal vessels were effectively restored or prevented with treatment of rottlerin, transfection of PKC-delta-DN, or siRNA for PKC delta. Interestingly, PKC delta translocated from cytosol to membrane in advanced glycation end product-treated human retinal microvascular endothelial cells, which was blocked by PKC delta inhibition. Taken together, PKC delta activation, related to its subcellular translocation, is involved in vascular permeability in response to diabetes, and inhibition of PKC delta effectively restores loss of tight junction proteins in retinal vessels. Therefore, we suggest that inhibition of PKC delta could be an alte...Continue Reading

References

Nov 1, 1975·The British Journal of Ophthalmology·J Cunha-VazA J Campos
Jun 16, 1997·The Journal of Cell Biology·A SakakibaraS Tsukita
Mar 31, 1998·Diabetes·M MizutaniM Lorenzi
Jun 26, 1998·The Biochemical Journal·H Mellor, P J Parker
Feb 22, 2000·American Journal of Ophthalmology·M K DavidsonF R Haselton
Apr 12, 2000·Seminars in Ophthalmology·D A AntonettiT W Gardner
Aug 18, 2001·Diabetologia·M Lorenzi, C Gerhardinger
Dec 19, 2002·Diabetologia·M Porta, F Bandello
Jun 11, 2004·The New England Journal of Medicine·Einar Stefánsson
Aug 8, 2006·Journal of Biochemistry and Molecular Biology·Jung Hun KimKyu-Won Kim
Aug 29, 2006·Diabetes·David A AntonettiUNKNOWN JDRF Diabetic Retinopathy Center Group
Oct 27, 2006·Investigative Ophthalmology & Visual Science·Nicole S HarhajDavid A Antonetti
Apr 20, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yoon Kyung ChoiKyu-Won Kim
May 4, 2007·The British Journal of Ophthalmology·Jeong Hun KimKyu-Won Kim
Sep 14, 2007·Current Eye Research·Jeong Hun KimBon-Hong Min
Oct 19, 2007·Biochemical and Biophysical Research Communications·Julhash U Kazi, Jae-Won Soh
Nov 10, 2007·Endocrine·Jaime A DavidsonPamela W Anderson
Dec 25, 2008·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Jeong Hun KimKyu-Won Kim

❮ Previous
Next ❯

Citations

May 26, 2011·Current Diabetes Reports·Jennifer T Durham, Ira M Herman
Nov 6, 2010·Archives of Pharmacal Research·Dong Hyun JoJeong Hun Kim
Nov 19, 2011·Clinical and Experimental Pharmacology & Physiology·Yingxue SuBanghao Zhu
Mar 10, 2012·American Journal of Physiology. Cell Physiology·Robert R RigorSarah Y Yuan
Jun 22, 2013·Journal of Biomedical Science·Dong Hyun JoJeong Hun Kim
Jan 18, 2014·Biochemical and Biophysical Research Communications·Hyun Beom SongJeong Hun Kim
Mar 8, 2013·Future Medicinal Chemistry·Megha BarotAshim K Mitra
Feb 25, 2014·ISRN Ophthalmology·Joanna M TarrRakesh Chibber
Feb 4, 2012·Experimental Eye Research·Ariadna Yolanda Ruiz-LoredoAna María López-Colomé
Aug 12, 2010·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Colin L WillisThomas P Davis
Aug 31, 2011·Enzyme Research·Daniel J Loegering, Michelle R Lennartz
May 2, 2015·Journal of Ethnopharmacology·Leilei WangYibin Feng
Feb 18, 2015·Antioxidants & Redox Signaling·Ryan M Burke, Bradford C Berk
Jul 12, 2016·Current Eye Research·Karolien HollandersIngeborg Stalmans
Feb 22, 2012·The International Journal of Biochemistry & Cell Biology·Jin Hyoung KimJeong Hun Kim
Jul 6, 2010·Biochemical Pharmacology·M AmadioA Pascale
Jun 3, 2017·Current Eye Research·Cristina Solà-AdellRafael Simó
Aug 14, 2012·Medicinal Research Reviews·Robert R RigorSarah Y Yuan
Sep 26, 2013·Molecular Biology Reports·Yan-Jun HuWan-Xi Yang
Jun 20, 2020·International Ophthalmology·Haijiang ZhangLiye He
Jan 13, 2011·Journal of Leukocyte Biology·Joilson O Martins
Apr 27, 2013·Diabetes, Obesity & Metabolism·B Shao, U Bayraktutan
Mar 18, 2011·Journal of Neuroscience Research·Jin Hyoung KimJeong Hun Kim
Sep 8, 2021·Frontiers in Pharmacology·Claudio BucoloAlessia Pascale

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
Jeong Hun KimKyu-Won Kim
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
Jin Hyoung KimYoung Suk Yu
© 2021 Meta ULC. All rights reserved